The event aimed at looking at different approaches to diabetes management and explore options for patient care
Singapore recently, hosted ‘The 10th International Diabetes Federation – Western Pacific Region Congress and 6th Asian Association for the Study of Diabetes Scientific Meeting’. A symposium, ‘Directions in Diabetes – Exploring Options for Patient Care’ was also a part of the event which aimed at discovering different approaches to diabetes management and explore options for patient care across regions.
Renowned pharma firms, Boehringer Ingelheim and Eli Lilly and Company, conducted a media briefing on ‘Directions in Diabetes- Exploring Options for Patient Care,’ where various issues related to Type II diabetes (T2D) were discussed by expert doctors. Dr Jisoo Lee of Boehringer Ingelheim talked about investigating early treatment conversations in T2D. Lee also spoke about IntroDia, which is the largest multinational survey of its kind to date investigating early conversations between physicians and people with T2D. Dr Kevin Tan spoke about DDP-4 inhibition: An effective management approach in T2D.
Tan narrated the highlights of the data presented at Asian Association for the Study of Diabetes (AASD). The topic of discussion for Dr Chung Horn Lee was SGLT2 inhibition: An important treatment option in T2D management.
EP News Bureau – Mumbai